Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

12,012,000 7,440,000

Capital lease obligation, less current

portion 16,000 22,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock -- $.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock -- $.001 par value;

authorized 325,000,000 shares;

outstanding -- 226,210,617 and 226,210,617,

respectively 226,000 226,000

Additional paid-in capital 246,476,000 246,205,000

Accumulated deficit (235,922,000) (230,836,000)

Total stockholders' equity 10,780,000 15,595,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $22,808,000 $23,057,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED

July 31, 2008 July 31, 2007

Unaudited Unaudited

REVENUES:

Contract manufacturing revenue $1,193,000 $1,621,000

Government contract revenue 324,000 -

License revenue - 4,000

Total revenues 1,517,000 1,625,000

COSTS AND EXPENSES:

Cost of contract manufacturing 903,000 1,181,000

Research and development 4,068,000 3,624,000

Selling, general and administrative 1,706,000 1,708,000

Total costs and expenses 6,677,000 6,513,000

LOSS FROM OPERATIONS (5,160,000) (4,888,000)

OTHE
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... 2011 Sangui enters commercialization phase / Initial ... State of Tamaulipas has issued an initial order of Hemo2Spray, ... wound debridement product Scabremove both registered by the Mexican authorities ... order of the wound spray and Sangui management is positive ...
... and myeloma are both malignant diseases that arise from ... lymph nodes and the bone marrow. Although considerable progress ... they remain a significant challenge for patients and their ... for lymphoma and myeloma will be presented today at ...
... Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... ® in the U.S. and XIAPEX ® ... George Gould, Esq., to its Board of Directors effective ... of George M. Gould, LLC, and of counsel to ...
Cached Biology Technology:Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management 2Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 2Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 3Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 4Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 5Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 6Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 7Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 8Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 9BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... . Our eyes ... us with a continuous stream of information about our own ... in a car the world glides by us and ... effort, our brain calculates self-motion from this "optic flow". This ... gaze during our own movements. Together with biologists from the ...
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... than 200 million people worldwide and is a ... Osteoporosis Foundation. Resistance training often is recommended to ... (BMD), although previous studies that examined the effects ... Now, in a new study, University of Missouri ...
... cells tighten their belts: they start to digest their ... as autophagy - takes place in special organelles called ... have developed as a means of survival when times ... has become a kind of self-cleaning process. In mammalian ...
... team at the Centre for Stem Cell Research in Cambridge ... http://dev.biologists.org/ ) a new and safer way of generating pluripotent ... to every tissue of the body. Rapid developments in stem ... stem cell scientists to convert specialised cells, such as skin ...
Cached Biology News:Building strong bones: Running may provide more benefits than resistance training, MU study finds 2Self-digestion as a means of survival 2Researchers piggyback to safer reprogrammed stem cells 2
... The Jouan RC Maxi MB (for aqueous, ... vacuum concentrator/centrifugal evaporator systems respond to specific ... rapid and safe concentration of heat-labile samples. ... pumps, different of cold traps and a ...
... concentrator for efficient drying of small volumes ... system combines the SpeedVac™ Concentrator and chemically ... pump and rotor control, and dual timers ... time), makes the DNA120 indispensable in the ...
... Start up kit. Includes configured Laptop PC ... 1 MultiBlock satellite thermal Cycler (non-robotic). ... User friendly software. Store/track run data. ... lid. Outstanding uniformity. Advanced control ...
... Thermal Cycler is Thermo Electron's most advanced ... with easy to use sophisticated onboard software ... programming. Designed to offer performance, accuracy and ... a number of customer driven features built ...
Biology Products: